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be clinically acceptable for treatment while achieving critical 
serial organ dose constraints, with representative results 
shown in Figure 1. IMPT revealed significantly better PTV 
conformity (p=0.008) and significant reductions in mean dose 
to several distant structures including larynx (p=0.002) and 
brain (p=0.006) against both VMAT and TomoHD plans. 
 
IMPT plans were more susceptible to anatomical changes 
compared to VMAT in nasal cavity filling simulation (e.g. 
mean reduction in CTV65 D98%: 1.9 vs 0.4 Gy) and weight loss 
(e.g. mean increase in cord D2%: 2.2 vs 0.2 Gy). 
Conclusions: For the NPC cases studied, high quality plans 
were generated with all three techniques. IMPT 
demonstrated better PTV conformity and reduced dose to 
peripheral structures, the clinical significance of which is yet 
to be determined. On the other hand, IMPT was more 
susceptible to clinically observable anatomical changes.  
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The aim of radiation oncology is to eradicate tumor tissue 
while attempting to preserve function of adjacent organs and 
tissues. In the treatment of thoracic tumors the heart is often 
at risk. Finding an optimum between the probability of curing 
the patient and the risk of inducing complications requires 
e.g. predictive models for the risk of such complications. 
Current predictive models are generally based on one or 
more dose metrics, such as the (generalized) mean dose, 
volume receiving at least a defined minimum dose or the 
minimum dose to a defined fraction of the cardiac volume. 
The selection of these metrics, however, is generally based 
on assumed mechanisms and/or epidemiological parameter 
selection methods. As such, we hypothesized that a better 
understanding of mechanisms underlying cardiac damage may 
lead to improved selection of dose metrics for predictive 
models. 
We performed a number of studies on mechanisms of cardiac 
toxicity using the irradiated rat as a model. In short, thoracic 
sub-volumes were irradiated using high-precision proton 
irradiation to yield varying irradiated cardiac and lung 
volumes. We analyses cardiac and pulmonary histological and 
function changes and found that heart irradiation already 
resulted in cardiac damage at 8 weeks post-irradiation [1]. 
Moreover, we found that this damage was aggravated if also 
the lung was irradiated [1,2]. Finally, we found that 
Captopril could both ameliorate the cardiac damage and its 
impact on lung damage and function. Therefore we 
concluded that the radiation response of heart and lung are 
closely related and cannot be regarded independently. As 
such, adding dosimetric and/or clinical parameters related to 
the lung in the development of predictive models for 
radiotherapy-induced cardiac damage may improve the 
accuracy of such model.  
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This presentation gives an overview of research performed in 
rat models of localized heart irradiation to address 
mechanisms by which ionizing radiation injures the heart. Rat 
models with mutations in the c-kit receptor gene have been 
used to investigate the role of mast cells in radiation-induced 
heart disease. The role of transforming growth factor-beta 
has been assessed by its pharmacological induction and the 
inhibition of its receptors. Moreover, rat models have been 
used to investigate whether the effects of radiation in the 
heart are different when radiation is combined with tyrosine 
kinase inhibitors, which have recently been associated with 
their own adverse cardiac effects.  
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A number of epidemiological studies have recently provided 
insight into the magnitude of the risk of heart disease 
occurring as a result of radiotherapy and into the factors that 
affect the risk.  In this talk, some of these results will be 
described. 
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Purpose/Objective: Adjuvant radiotherapy (RT) for left-sided 
breast cancer increases long term cardiac morbidity and 
mortality. No safe radiation threshold for heart is known. 
Troponin T is a sensitive marker of acute myocardial damage. 
Our aim was to evaluate the effects of left-sided breast 
cancer RT on high sensitivity cardiac troponin T (hscTnT) 
levels and possible associations with cardiac radiation doses 
and echocardiographic parameters. 
Materials and Methods: A total of 58 patients with an early 
stage left-sided breast cancer or ductal carcinoma in situ 
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(DCIS) addressed for adjuvant breast RT without prior 
chemotherapy were included in this prospective, non-
randomized study. RT was delivered with opposing tangential 
photon fields for the breast only with either conventional 
50/2 Gy or hypofractionated 42.56/2.66 Gy regimens (n=57) 
or with electron beams for the thoracic wall after 
mastectomy (n=1). Blood samples were taken before, during 
and after RT. A comprehensive 2D echocardiography and 
electrocardiogram (ECG) were done prior and after RT. Dose-
volume-histograms (DVHs) were generated for the whole 
heart, left ventricle (LV) and left anterior descending 
coronary artery (LAD). The patients were divided into two 
groups based on an predefined 30% increase from the 
baseline in hscTnT serum values.  
Results: The baseline characteristics are presented in Table 
1. HscTnT increased during RT more than 30% in 12/58 
patients (21%). When comparing patients with increased 
hscTnT values (Group A) (N=12) to patients without hscTnT 
increase (Group B) (N=46) the radiation doses to cardiac 
structures (area under the curve in DVHs) were significantly 
higher in group A for the whole heart (p=0.02) and LV 
(p=0.03). Significant differences were observed in volumes 
receiving 5, 10, 15 and 20 Gy as presented in Figure 1.. For 
LAD, differences between groups A and B were found in 
volumes receiving 15 (p=0.047) and 20 Gy (p=0.04). 
Furthermore, in echocardiographic measurements the 
interventricular septum thickened (p=0.01) and LV´s diastolic 
deceleration time increased (p=0.008) more in the group A 
when compared to the group B (Table 1.). In ECG, moderate 
T-wave alterations were observed in 3/12 (25%) recordings 
after RT among the group A and 13/46 (28%) among the group 






Conclusions: The increase in hscTnT level during adjuvant RT 
associated positively with cardiac radiation doses in 
chemotherapy naive breast cancer patients. Such subclinical 
cardiotoxicity detected by hscTnT may be related to excess 
long term cardiovascular mortality and morbidity. Further 
follow-up of our patients and additional studies are 
warranted to confirm the clinical relevance of this finding. 
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Purpose/Objective: We performed a population-based 
assessment for the all-cause and cardiopulmonary mortality 
risk in esophageal cancer (EC) patients treated with 
chemotherapy and radiation, comparing conventional 
radiotherapy (CRT) or Intensity Modulated Radiation Therapy 
(IMRT). 
Materials and Methods: We identified 2,578 patients older 
than age 65 years from the SEER/Texas Cancer Registry-
Medicare databases who had non-metastatic EC diagnosed 
between 2002 and 2009 (CRT=2,265; IMRT=313). We defined 
radiation modality by delivery claims, whether it is by 
conventional radiation therapy, which could either be 2D or 
3D (CRT: HCPCS: 77401-77416) or by IMRT delivery (HCPCS 
77418, G0174) within 6 months of diagnosis. Patients in both 
cohorts were compared using propensity score-based 
adjustment. Cause-specific and overall mortality rates were 
evaluated using Kaplan-Meyer lifetest and multivariate (MVA) 
Cox proportional hazard models.  
Results: Except for marital status, year of diagnosis, and 
SEER region, both radiation cohorts were well balanced for 
various patient, tumor, and treatment characteristics, 
including the distribution of the use of IMRT vs. CRT in 
urban/metro or rural areas. CRT was primarily done by 3D 
delivery (98.9%). IMRT use increased from 2.6% in 2002 to 30% 
in 2009, while 3DCRT use decreased from 97.4% in 2002 to 
